Core One Labs Acquires New Path Laboratories
December 23, 2021
Core One Labs Inc. has completed the acquisition of all outstanding share capital of New Path Laboratories Inc., a British Columbia-based developer and manufacturer of natural health products and functional mushroom dietary supplements. The deal was paid in common shares of Core One and is intended to expand Core One's presence in the functional mushrooms market and add retail distribution channels to generate sales revenue.
- Buyers
- Core One Labs Inc.
- Targets
- New Path Laboratories Inc.
- Sellers
- Shareholders of New Path Laboratories Inc.
- Industry
- Food & Beverage
- Location
- British Columbia, Canada
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Core One Labs Acquires Awakened Biosciences
February 11, 2022
Biotechnology
Core One Labs Inc. (CSE: COOL) has completed the acquisition of all outstanding share capital of Awakened Biosciences Inc., adding Awakened's provisional patents and novel synthetic psilocybin production technologies to Core One's portfolio. The deal expands Core One's R&D and manufacturing capabilities in psychedelic therapeutics and secures IP that could enable lower-cost, scalable production and potential near-term revenue from non-controlled psilocybin-based compounds.
-
Core One Labs Acquires Akome Biotech
April 29, 2021
Biotechnology
Core One Labs Inc. (CSE: COOL), a Vancouver-based biotechnology company, entered into a definitive share purchase agreement to acquire all outstanding share capital of Akome Biotech Ltd. Core One will issue 3,500,000 common shares to Akome’s shareholders as consideration; the acquisition expands Core One’s psychedelic-therapeutics R&D capabilities targeting stroke, Alzheimer’s, Parkinson’s and depression.
-
NeoGenomics Acquires Pathline
April 7, 2025
Healthcare Services
NeoGenomics, Inc. (NASDAQ: NEO) has completed its acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified pathology laboratory headquartered in Ramsey, New Jersey. The deal strengthens NeoGenomics' commercial presence in the Northeast United States and expands its molecular and hematology-oncology testing capabilities and access to its oncology test menu.
-
StatLab Medical Products Acquires CellPath Ltd.
June 8, 2022
Medical Devices
StatLab Medical Products, a portfolio company of Audax Private Equity and Linden Capital Partners, acquired UK-based CellPath Ltd., a manufacturer and supplier focused on the histology and cytology markets. The deal adds injection-molding manufacturing capabilities, proprietary products (including the CellNass archiving service), and an established European customer base to support StatLab's international growth.
-
SourceBio International plc Acquires LDPath Limited
March 29, 2022
Healthcare Services
SourceBio International plc has completed a strategic acquisition of LDPath Limited, a London-based digital pathology testing provider. The deal expands SourceBio's digital and AI-enabled pathology capabilities and creates a larger private provider of cellular and digital pathology services for the U.K. healthcare market.
-
Boosted Commerce Acquires WellPath
November 23, 2021
Consumer Products
Boosted Commerce has acquired WellPath, a direct-to-consumer nutritional supplements brand, to expand its wellness and personal care portfolio. Boosted plans to scale WellPath through new product development, expanded marketing (including offline channels), and leveraging its e-commerce operating playbook.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.